Retrospective observational study comparing comparing post-COVID conditions incidence in COVID-19 patients between ensitrelvir administration and administration/non-administration of anti-SARS-CoV-2 drugs using large-scale health insurance association data in Japan (3-month follow-up)

Retrospective observational study comparing comparing post-COVID conditions incidence in COVID-19 patients between ensitrelvir administration and administration/non-administration of anti-SARS-CoV-2 drugs using large-scale health insurance association data in Japan (3-month follow-up) - Retrospective observational study comparing comparing post-COVID conditions incidence in COVID-19 patients between ensitrelvir administration and administration/non-administration of anti-SARS-CoV-2 drugs using large-scale health insurance association data in Japan (3-month follow-up)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053278

Enrollment

300000

Registered

2024-01-09

Start date

2024-01-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients whose index month (IM) of COVID-19 diagnosis is during the enrollment period (2022/11 to 2023/05). 2. Patients with observable period of 6 months before IM 3. Patients with observable period up to 3 months after IM

Exclusion criteria

Exclusion criteria: 1. Patients under 18 years of age at the time of IM 2. Patients with dispending days of multiple anti-SARS-CoV-2 drugs in IM 3. Patients with a COVID-19 diagnosis within 3 months prior to IM 4. Patients who have been diagnosed with the same event as the post-COVID condition within 6 months before IM 5. Patients at risk of severe COVID-19

Design outcomes

Primary

Measure	Time frame
Post-COVID conditions incidence from 2 to 3 months after the month of diagnosis of COVID-19	—

Countries

Japan

Contacts

Public ContactTakuji Komeda

Shionogi & Co., Ltd. Data Science Department

takuji.komeda@shionogi.co.jp070-7812-6558

Outcome results